<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" xml:lang="EN" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Pharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">282</journal-id><journal-id journal-id-type="pmc-domain">brjpharm</journal-id><journal-title-group><journal-title>British Journal of Pharmacology</journal-title></journal-title-group><issn pub-type="ppub">0007-1188</issn><issn pub-type="epub">1476-5381</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC2013984</article-id><article-id pub-id-type="pmcid-ver">PMC2013984.1</article-id><article-id pub-id-type="pmcaid">2013984</article-id><article-id pub-id-type="pmcaiid">2013984</article-id><article-id pub-id-type="pmid">17420778</article-id><article-id pub-id-type="doi">10.1038/sj.bjp.0707234</article-id><article-id pub-id-type="pii">0707234</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Papers</subject><subj-group><subject>Cardiovascular and Pulmonary Pharmacology</subject></subj-group></subj-group></article-categories><title-group><article-title>Pharmacokinetic-pharmacodynamic modelling of <italic>S</italic>(&#8722;)-atenolol in rats: reduction of isoprenaline-induced tachycardia as a continuous pharmacodynamic endpoint</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>van Steeg</surname><given-names initials="TJ">T J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Freijer</surname><given-names initials="J">J</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Danhof</surname><given-names initials="M">M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>de Lange</surname><given-names initials="ECM">E C M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib></contrib-group><aff id="aff1"><label>1</label><institution>Division of Pharmacology, Leiden Amsterdam Center for Drug Research, Leiden University</institution> Leiden, <country>The Netherlands</country></aff><aff id="aff2"><label>2</label><institution>LAP&amp;P Consultants BV</institution> Leiden, <country>The Netherlands</country></aff><author-notes><corresp id="caf1"><label>*</label>Author for correspondence: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:l.lange@lacdr.leidenuniv.nl">l.lange@lacdr.leidenuniv.nl</email></corresp></author-notes><pub-date pub-type="epub"><day>10</day><month>04</month><year>2007</year></pub-date><pub-date pub-type="collection"><day>28</day><month>05</month><year>2007</year></pub-date><pub-date pub-type="ppub"><month>06</month><year>2007</year></pub-date><volume>151</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">151430</issue-id><fpage>356</fpage><lpage>366</lpage><history><date date-type="received"><day>09</day><month>11</month><year>2006</year></date><date date-type="rev-recd"><day>08</day><month>01</month><year>2007</year></date><date date-type="accepted"><day>05</day><month>02</month><year>2007</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>06</month><year>2008</year></date></event><event event-type="pmc-live"><date><day>01</day><month>06</month><year>2008</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2010-12-24 12:31:49.080"><day>24</day><month>12</month><year>2010</year></date></event></pub-history><permissions><copyright-statement>Copyright 2007, Nature Publishing Group</copyright-statement><copyright-year>2007</copyright-year><copyright-holder>Nature Publishing Group</copyright-holder></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="0707234a.pdf"/><abstract><sec><title>Background and purpose:</title><p>For development of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) models, continuous recording of drug effects is essential. We therefore explored the use of isoprenaline in the continuous measurement of the cardiovascular effects of antagonists of &#946;-adrenoceptors (&#946;-blockers). The aim was to validate heart rate as a pharmacodynamic endpoint under continuous isoprenaline-induced tachycardia by means of PK-PD modelling of <italic>S</italic>(&#8722;)-atenolol.</p></sec><sec><title>Experimental approach:</title><p>Groups of WKY rats received a 15 min iv infusion of 5 mg kg<sup>&#8722;1</sup> <italic>S</italic>(&#8722;)-atenolol, with or without iv infusion of 5 &#956;g kg<sup>&#8722;1</sup> h<sup>&#8722;1</sup> isoprenaline. Heart rate was continuously monitored and blood samples were taken.</p></sec><sec><title>Key results:</title><p>A three-compartment model best described the pharmacokinetics of <italic>S</italic>(&#8722;)-atenolol. The PK&#8211;PD relationship was described by a sigmoid Emax model and an effect compartment was used to resolve the observed hysteresis. In the group without isoprenaline, the variability in heart rate (30&#8201;b.p.m.) approximated the maximal effect (<italic>E</italic>
<sub>max</sub>=43&#177;18&#8201;b.p.m.), leaving the parameter estimate of potency (<italic>EC</italic>
<sub>
<italic>50</italic></sub>=28&#177;27 ng ml<sup>&#8722;1</sup>) unreliable. Both precise and reliable parameter estimates were obtained during isoprenaline-induced tachycardia: 517&#177;13 b.p.m. (<italic>E</italic>
<sub>
<italic>0</italic></sub>), 168&#177;15&#8201;b.p.m. (<italic>E</italic>
<sub>max</sub>), 49&#177;14 ng ml<sup>&#8722;1</sup> (<italic>EC</italic>
<sub>
<italic>50</italic></sub>), 0.042&#177;0.012 min<sup>&#8722;1</sup> (<italic>k</italic>
<sub>
<italic>eo</italic></sub>) and 0.95&#177;0.34 (<italic>n</italic>).</p></sec><sec><title>Conclusions and implications:</title><p>Reduction of heart rate during isoprenaline-induced tachycardia is a reliable pharmacodynamic endpoint for &#946;-blockers <italic>in vivo</italic> in rats. Consequently this experimental approach will be used to investigate the relationship between drug characteristics and <italic>in vivo</italic> effects of different &#946;-blockers.</p></sec></abstract><kwd-group><kwd><italic>S</italic>(&#8722;)-atenolol</kwd><kwd>isoprenaline</kwd><kwd>PK&#8211;PD modelling</kwd><kwd>rats</kwd><kwd>heart rate</kwd><kwd>tachycardia</kwd><kwd><italic>&#946;</italic>-blockers</kwd><kwd>NONMEM</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>